Annexon, Inc. Common Stock
$3.93
$0.01 (+0.26%)
$3.88Day Range$4.00
Key Statistics
Market Cap
$743.15M
Shares Outstanding
189.6M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Jul 24, 2020
Round Lot
100
Locale
US
Trading Data
Day Open
$3.91
Day High
$4.00
Day Low
$3.88
Volume
4.52M
VWAP
$3.95
Prev Close
$3.92
Transactions
--
Acc. Volume
--
About Annexon, Inc. Common Stock
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502, for Oral small molecule; and ANX009, for systemic autoimmune diseases.
PHARMACEUTICAL PREPARATIONSSIC 283492 employees1400 SIERRA POINT PARKWAY, BRISBANE, CA, 94005(650) 822-5500IPO Jul 24, 2020US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001528115
- Composite FIGI
- BBG007QVDFG2
- Share Class FIGI
- BBG007QVDFH1
- Ticker Root
- ANNX
- SIC Code
- 2834
About Annexon, Inc. Common Stock (ANNX) Stock
Annexon, Inc. Common Stock (ANNX) closed the 2026-09-16 session at $3.93, up 0.26% versus the previous close (+0.01). The stock opened at $3.91 and traded between $3.88 and $4.00 during that session. Session trading volume was 4.5M shares. The volume-weighted average price (VWAP) is $3.95.
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502, for Oral small molecule; and ANX009, for systemic autoimmune diseases.
Annexon, Inc. Common Stock has a market capitalization of $743.2 million. The company operates in the PHARMACEUTICAL PREPARATIONS industry classification. ANNX is listed on the XNAS exchange. The company employs approximately 92 people. Annexon, Inc. Common Stock is headquartered in BRISBANE, CA. The recorded listing date is 2020-07-24.
On this page you can find market ANNX stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the PHARMACEUTICAL PREPARATIONS sector.